Patents matching “combination”

US 11007184

Cancer treatments using combinations of type 2 MEK and ERK inhibitors

Biomed Valley Discoveries, Inc. · Granted May 18, 2021 · Expires May 13, 2041

US 10966977

Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders

TG Therapeutics, Inc. · Granted Apr 6, 2021 · Expires Apr 1, 2041

US 10959938

Combination of (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent

QUANTUM GENOMICS · Granted Mar 30, 2021 · Expires Mar 25, 2041

US 10952993

Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs

VTV THERAPEUTICS LLC · Granted Mar 23, 2021 · Expires Mar 18, 2041

US 10952980

GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes

The Regents of the University of California · Granted Mar 23, 2021 · Expires Mar 18, 2041

US 10953000

Combination of pimavanserin and cytochrome P450 modulators

ACADIA Pharmaceuticals Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

US 10946080

Compositions and methods for combination therapy with dengue virus and dendritic cells

PrimeVax Immuno-Oncology · Granted Mar 16, 2021 · Expires Mar 11, 2041

US 10946009

Combination dosage form of a mu opioid receptor antagonist and an opioid agent

Theravance Biopharma R&D IP, LLC · Granted Mar 16, 2021 · Expires Mar 11, 2041

US 10946000

Method for treating cancer with combination therapy

RedHill Biopharma Ltd. · Granted Mar 16, 2021 · Expires Mar 11, 2041

US 10933076

Crocin-sorafenib combination therapy for liver cancer

UNITED ARAB EMIRATES UNIVERSITY · Granted Mar 2, 2021 · Expires Feb 25, 2041

US 10918648

Estrogen receptor modulator combinations

The Regents of the University of California · Granted Feb 16, 2021 · Expires Feb 11, 2041

US 10912751

Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease

Esperion Therapeutics, Inc. · Granted Feb 9, 2021 · Expires Feb 4, 2041

US 10905692

Combination therapy for treating malignancies

Agios Pharmaceuticals, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

US 10905752

VEGFR-2 targeting DNA vaccine for combination therapy

Vaximm AG · Granted Feb 2, 2021 · Expires Jan 28, 2041

US 10898475

Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof

VTV THERAPEUTICS LLC · Granted Jan 26, 2021 · Expires Jan 21, 2041

US 10894044

Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer

The Board of Regents of the University of Texas System · Granted Jan 19, 2021 · Expires Jan 14, 2041

US 10881666

Combination pharmaceutical agents as RSV inhibitors

Enanta Pharmaceuticals, Inc. · Granted Jan 5, 2021 · Expires Dec 31, 2040

LT 3254695

COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER

ASTELLAS PHARMA INC [JP] · Granted Dec 28, 2020 · Expires Dec 23, 2040

US 10849960

Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 1, 2020 · Expires Nov 26, 2040

US 10835595

PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy

Inovio Pharmaceuticals, Inc. · Granted Nov 17, 2020 · Expires Nov 12, 2040

US 10813909

Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer

The Regents of the University of California · Granted Oct 27, 2020 · Expires Oct 22, 2040

US 10806740

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Oct 20, 2020 · Expires Oct 15, 2040

US 10799584

Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents

THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Oct 13, 2020 · Expires Oct 8, 2040

US 10799512

Estrogen combination for treatment of multiple sclerosis

The Regents of the University of California · Granted Oct 13, 2020 · Expires Oct 8, 2040